Blood tests may help to create personalized treatments for advanced prostate cancer
A simple blood test helps devise a personalized treatment for men with advanced prostate cancer.
The new test costs less than 50 pounds, can predict which patients are likely to respond to new targeted drugs and who can better cope with alternative therapies.It looks for multiple copies of the androgen receptor gene, which is a hormone-sensitive molecule that helps the growth of many prostate cancers.
Men with multiple copies of this gene did not respond very well to avilaterone and enzartamide drugs used in the treatment of advanced prostate cancer.
This drug is given to men who began spreading, cancer no longer responds to traditional hormonal therapy.
"Abraterone and enzaltamide are excellent treatments for advanced prostate cancer, and some men can take these drugs for years, cancer.
"But in other men these drugs do not work well and the disease returns rapidly.Actually, licensed exams for the doctor to choose whether these are the best treatment for individuals There is none.
"We select a male with advanced prostate cancer who is more likely to respond to Aviraterone and Enzaltamide and choose a robust clinic that can be used in a clinic to select a male who may need alternative treatment We developed a test.
"Our method is less than 50 pounds and can provide results quickly and can be carried out at NHS hospital laboratories to evaluate this trial in a future clinical trial and evaluate one of the standard patient care I hope to become a department.
In this study published in Annals of Oncology, blood samples from patients participating in three different clinical trials were taken.
In the initial study of 171 patients, men found to have multiple copies of the androgen receptor gene had a 4-fold higher mortality rate than those who had negative test results.
Men with multiple copies of 94 second group genes responded to avilaterone and enzaltamide 8 fold shorter than animals with 1 or 2 copies.
It has already been known that the androgen receptor plays an important role in cancers resistant to the two drugs.
Dr. Ian Frame, Director of Research for UK Prostate Cancer, who funded the study, said, "In order to stop prostate cancer from dying, it is necessary to treat all treatments as one.
"This test will be an important step toward that, we are closely watching the development"
Dr. Emma Smith of Cancer Research UK (which contributed to financing) said, "If it is further confirmed that this exam is reliable, for men who prostate cancer may not respond to standard treatment,
Every year about 41,000 men in the UK are diagnosed with prostate cancer and 11,000 have died of this disease.
EmoticonEmoticon